Watchlist · 75/100Aug 30, 12:43 PM EDT
Alnylam's Amvuttra Shows Broad Efficacy in ATTR; Zilebesiran Subgroup Data Bolster Case
ALNY
Alnylam Pharmaceuticals presented new data at a medical meeting showing Amvuttra is effective across various transthyretin amyloidosis patient groups, including those previously treated with Pfizer's tafamidis. Additionally, subgroup analyses for its investiga…
- ▹Amvuttra data supports use across ATTR patient groups, including those on tafamidis, strengthening its competitive position.
- ▹Zilebesiran shows encouraging subgroup results, advancing its pipeline in hypertension.
Watchlist · 70/100Sep 1, 9:30 AM EDT
Vertex Taps Insider Jonathan Poole as CFO, Effective 2027
VRTX
Vertex Pharmaceuticals (VRTX) announced Jonathan Poole, its current SVP of Finance, will become EVP and CFO on January 1, 2027, succeeding Charles Wagner. Wagner will transition to an expanded COO role, focusing on integrating recent acquisitions. This leaders…
- ▹Leadership transition is routine; no impact on pipeline or regulatory momentum.
- ▹Vertex's strong commercial portfolio and platform offset single-asset risk in narrative.
Watchlist · 70/100Aug 31, 5:07 AM EDT
Amgen's Repatha Shows 20% Mortality Reduction in High-Risk Primary Prevention Patients
AMGN
Amgen announced that a pre-specified analysis of the Phase 3 VESALIUS-CV trial showed Repatha (evolocumab) reduced the risk of death by 20% in high-risk patients without prior cardiovascular events when added to statin therapy. This data expands the potential…
- ▹Positive Phase 3 data showing 20% mortality reduction could support label expansion and reimbursement.
- ▹Repatha is a commercialized product with established manufacturing and Amgen's scale, but single-asset news limits technology score.
Watchlist · 65/100Aug 30, 5:59 PM EDT
United Therapeutics Showcases New Ralinepag and Inhaled Treprostinil Data to Bolster FDA Submissions
UTHR
United Therapeutics (UTHR) is presenting new analyses of ralinepag and inhaled treprostinil at European medical conferences, leveraging data from the Phase 3 ADVANCE OUTCOMES study. These presentations aim to strengthen its FDA filings for expanded indications…
- ▹New data supports FDA filings for ralinepag and inhaled treprostinil, with no recent regulatory negatives.
- ▹Multiple assets in pulmonary disease pipeline, but single-asset focus and trial-stage status cap upside.
High Risk · 47/100Sep 1, 12:10 AM EDT
Trump Announces Drug-Pricing Agreements with Astellas, BeOne, and Other Biotechs
ALPMFONCPFENVO
President Trump unveiled new drug-pricing accords with several pharmaceutical companies, including Astellas and BeOne Medicines, aimed at reducing healthcare costs for U.S. consumers. The agreements could impact revenue streams for these biotechs, making them…
- ▹Drug-pricing accords may pressure revenues for involved companies, but no direct FDA regulatory impact.
- ▹News is policy-driven, not company-specific; limited technology or commercial differentiation.
High Risk · 38/100Aug 31, 1:44 PM EDT
Hyperliquid's $13.7B Open Interest Pressures CME and Cboe; Kraken Deal Rumored
PURRCME
Hyperliquid's open interest surged to $13.7B, signaling growing competition for traditional exchanges like CME and Cboe, whose shares dipped. Reports of Hyperliquid in talks with Kraken's parent could further disrupt the derivatives market, making this a key d…
- ▹Decentralized exchange with no FDA relevance; regulatory uncertainty high.
- ▹Single-asset micro-cap with no clear moat or revenue visibility.
High Risk · 37/100Sep 1, 4:47 AM EDT
PMV Pharma Raises $50.8M in Oversubscribed IPO
PMVP
PMV Pharmaceuticals (PMVP) priced its IPO at $1.21 per share, raising approximately $50.8 million in gross proceeds from the sale of 22.055 million shares and pre-funded warrants. The oversubscribed offering includes additional warrants, providing the company…
- ▹Single-asset micro-cap with no clinical data yet, high dilution from IPO and warrants.
- ▹No regulatory clarity, no commercial product, and limited platform differentiation.
High Risk · 37/100Aug 31, 4:13 PM EDT
Inventiva Appoints New COO Ahead of Pivotal MASH Data Readout
IVEVFIVA
Inventiva (IVA) has named Chris Benecchi as its new chief operating officer to spearhead operational readiness as the biotech gears up for the pivotal NATiV3 Phase 3 topline results for lanifibranor in MASH, expected in Q4 2026. This strategic hire signals the…
- ▹Single-asset company with no FDA approval yet, relying on Phase 3 results in 2026.
- ▹COO appointment is a minor operational update, not a major catalyst.
High Risk · 37/100Aug 31, 4:08 PM EDT
PMV Pharma Initiates Public Stock and Warrant Offering
PMVP
PMV Pharmaceuticals (PMVP) has launched an underwritten public offering of common stock and warrants, with the option to sell pre-funded warrants to certain investors. The offering size and terms are yet to be determined, and TD Cowen is the sole book-running…
- ▹Dilutive public offering raises capital but signals potential cash runway concerns.
- ▹Single-asset clinical-stage company with no commercial products and limited platform differentiation.
High Risk · 37/100Aug 31, 8:29 AM EDT
CollPlant Diversifies into Photonic Computing with LightSolver Acquisition
CLGN
CollPlant Biotechnologies (CLGN) has agreed to acquire LightSolver, an Israeli deep-tech firm specializing in photonic computing, marking a strategic pivot into supercomputing. The deal, expected to close this week, will be funded mainly with equity, including…
- ▹Pivot to photonic computing is a major strategic shift away from core biotech focus, creating high execution risk.
- ▹Equity-funded acquisition with milestone warrants implies dilution and uncertain near-term value.
High Risk · 27/100Aug 30, 3:01 PM EDT
Tenax uncovers potential benefit in severe PH subgroup despite Phase 3 failure
TENX
Tenax Therapeutics (TENX) reported that post-hoc analyses of its Phase 3 LEVEL trial indicate that oral levosimendan may improve outcomes in pulmonary hypertension patients with severely reduced exercise capacity, even though the trial missed its primary endpo…
- ▹Phase 3 trial missed primary endpoint, severe regulatory setback.
- ▹Subgroup benefit is exploratory and unlikely to support approval without new trial.
High Risk · 5/100Sep 1, 8:04 AM EDT
North Korean Hackers Dump $30M in Bitcoin on Hyperliquid
PURRHYPE-USDETH-USDKCS-USD
North Korean hackers have reportedly sold over $30 million in bitcoin on the Hyperliquid decentralized exchange over the past three weeks, according to blockchain data cited by CoinDesk. This event highlights security concerns in the crypto space and may impac…
- ▹News unrelated to biotech, no FDA or clinical relevance
- ▹No platform, commercial, or manufacturing aspects for scoring